NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) - Equities research analysts at HC Wainwright issued their FY2024 earnings per share estimates for NewAmsterdam Pharma in a report released on Monday, December 30th. HC Wainwright analyst E. Arce anticipates that the company will earn ($1.64) per share for the year. HC Wainwright has a "Buy" rating and a $48.00 price target on the stock. The consensus estimate for NewAmsterdam Pharma's current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for NewAmsterdam Pharma's Q4 2024 earnings at ($0.37) EPS, Q1 2025 earnings at ($0.45) EPS, Q2 2025 earnings at ($0.43) EPS, Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.88) EPS, FY2026 earnings at ($1.80) EPS, FY2027 earnings at ($1.78) EPS and FY2028 earnings at ($1.04) EPS.
NAMS has been the subject of a number of other reports. Scotiabank upped their price objective on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a "sector outperform" rating in a report on Wednesday, December 11th. Needham & Company LLC reissued a "buy" rating and set a $36.00 price objective on shares of NewAmsterdam Pharma in a report on Thursday, December 5th. Royal Bank of Canada restated an "outperform" rating and issued a $31.00 target price on shares of NewAmsterdam Pharma in a report on Thursday, September 5th. Finally, Piper Sandler reiterated an "overweight" rating and set a $37.00 price target on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $38.17.
Get Our Latest Stock Report on NewAmsterdam Pharma
NewAmsterdam Pharma Stock Performance
Shares of NAMS traded up $0.10 during mid-day trading on Wednesday, hitting $25.70. 892,480 shares of the company's stock were exchanged, compared to its average volume of 379,852. The firm has a fifty day moving average of $22.26 and a two-hundred day moving average of $19.26. NewAmsterdam Pharma has a twelve month low of $11.18 and a twelve month high of $27.29.
Insider Transactions at NewAmsterdam Pharma
In other news, major shareholder Nap B.V. Forgrowth sold 8,530 shares of the business's stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $25.02, for a total transaction of $213,420.60. Following the transaction, the insider now owns 11,812,033 shares in the company, valued at approximately $295,537,065.66. The trade was a 0.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders sold a total of 416,884 shares of company stock worth $10,676,428 over the last three months. 19.50% of the stock is currently owned by insiders.
Institutional Investors Weigh In On NewAmsterdam Pharma
Institutional investors have recently added to or reduced their stakes in the company. Banque Cantonale Vaudoise acquired a new stake in shares of NewAmsterdam Pharma during the 2nd quarter worth approximately $38,000. Quarry LP lifted its position in NewAmsterdam Pharma by 2,469.2% in the third quarter. Quarry LP now owns 6,500 shares of the company's stock worth $108,000 after purchasing an additional 6,247 shares during the period. Barclays PLC boosted its stake in NewAmsterdam Pharma by 1,813.4% during the third quarter. Barclays PLC now owns 7,596 shares of the company's stock worth $126,000 after buying an additional 7,199 shares in the last quarter. Bellevue Group AG bought a new stake in NewAmsterdam Pharma in the 3rd quarter valued at $128,000. Finally, XTX Topco Ltd acquired a new position in shares of NewAmsterdam Pharma in the 3rd quarter valued at $187,000. 89.89% of the stock is owned by institutional investors and hedge funds.
About NewAmsterdam Pharma
(
Get Free Report)
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Featured Articles
Before you consider NewAmsterdam Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NewAmsterdam Pharma wasn't on the list.
While NewAmsterdam Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
